Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation

Background and Objectives The goal of this work was to investigate the natural history and outcomes after treatment for spontaneous amyloid-related imaging abnormalities (ARIA)-like in cerebral amyloid angiopathy–related inflammation (CAA-ri). Methods This was a multicenter, hospital-based, longitudinal, prospective observational study of inpatients meeting CAA-ri diagnostic criteria recruited through the Inflammatory Cerebral Amyloid Angiopathy and Alzheimer's Disease βiomarkers International Network from January 2013 to March 2017. A protocol for systematic data collection at first-ever presentation and at subsequent in-person visits, including T1-weighted, gradient recalled echo–T2*, fluid-suppressed T2-weighted (fluid-attenuated inversion recovery), and T1 postgadolinium contrast-enhanced images acquired on 1.5T MRI, was used at the 3-, 6-, 12-, and 24-month follow-up. Centralized reads of MRIs were performed by investigators blinded to clinical, therapeutic, and time-point information. Main outcomes were survival, clinical and radiologic recovery, intracerebral hemorrhage (ICH), and recurrence of CAA-ri. Results The study enrolled 113 participants (10.6% definite, 71.7% probable, and 17.7% possible CAA-ri). Their mean age was 72.9 years; 43.4% were female; 37.1% were APOEε4 carriers; 36.3% had a history of Alzheimer disease; and 33.6% had a history of ICH. A history of ICH and the occurrence of new ICH at follow-up were more common in patients with cortical superficial siderosis at baseline (52.6% vs 14.3%, p < 0.0001 and 19.3% vs 3.6%, p < 0.009, respectively). After the first-ever presentation of CAA-ri, 70.3% (95% confidence interval [CI] 61.6%–78.5%) and 84.1% (95% CI 76.2%–90.6%) clinically recovered within 3 and 12 months, followed by radiologic recovery in 45.1% (95% CI 36.4%–54.8%) and 77.4% (95% CI 67.7%–85.9%), respectively. After clinicoradiologic resolution of the first-ever episode, 38.3% (95% CI 22.9%–59.2%) had at least 1 recurrence within the following 24 months. Recurrence was more likely if IV high-dose corticosteroid pulse therapy was suddenly stopped compared to slow oral tapering off (hazard ratio 4.68, 95% CI 1.57–13.93; p = 0.006). Discussion These results from the largest longitudinal cohort registry of patients with CAA-ri support the transient and potentially relapsing inflammatory nature of the clinical-radiologic acute manifestations of the disease and the effectiveness of slow oral tapering off after IV corticosteroid pulse therapy in preventing recurrences. Our results highlight the importance of differential diagnosis for spontaneous ARIA-like events in β-amyloid–driven diseases, including treatment-related ARIA in patients with Alzheimer disease exposed to immunotherapy drugs.

[1]  E. Chung,et al.  Moderate Aortic Stenosis in Patients With Heart Failure , 2022, Korean circulation journal.

[2]  L. Ferrucci,et al.  Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease , 2021, Ageing Research Reviews.

[3]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[4]  Nick C Fox,et al.  Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease , 2021, Neurology.

[5]  A. Izenberg,et al.  Clinical Reasoning: An 81-year-old woman with decreased consciousness and fluctuating right facial droop , 2020, Neurology.

[6]  D. Holtzman,et al.  Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA) , 2020, Alzheimer's & dementia.

[7]  M. Andjelkovic,et al.  Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis , 2019, Alzheimer's Research & Therapy.

[8]  P. Nichelli,et al.  A challenging diagnosis of reversible “vascular” dementia: Cerebral amyloid angiopathy-related inflammation , 2019, Journal of Neuroimmunology.

[9]  S. Black,et al.  Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. , 2019, International journal of stroke : official journal of the International Stroke Society.

[10]  Meagan Bailey,et al.  Pearls & Oy-sters: CAA-related inflammation presents as subacute cognitive decline in a patient with Parkinson disease , 2019, Neurology.

[11]  R. Sperling,et al.  The Future of Anti-Amyloid Trials , 2019, The Journal of Prevention of Alzheimer's Disease.

[12]  R. Carare,et al.  Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain , 2019, Front. Aging Neurosci..

[13]  E. Carrera,et al.  Clinical Reasoning: Rapid progression of reversible cognitive impairment in an 80-year-old man , 2018, Neurology.

[14]  H. Markus,et al.  Cerebral amyloid angiopathy associated with inflammation: A systematic review of clinical and imaging features and outcome. , 2018 .

[15]  D. Werring,et al.  Minimally symptomatic cerebral amyloid angiopathy-related inflammation: three descriptive case reports , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  Nick C Fox,et al.  Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab , 2018, Neurology.

[17]  Eric E. Smith,et al.  The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  Keith A. Johnson,et al.  Florbetapir-PET to diagnose cerebral amyloid angiopathy , 2016, Neurology.

[19]  Blaine R. Roberts,et al.  The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer’s Disease Cohorts , 2016, Journal of Molecular Neuroscience.

[20]  F. Pasquier,et al.  Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer’s disease: A review , 2016, Ageing Research Reviews.

[21]  M. Frosch,et al.  Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. , 2016, JAMA neurology.

[22]  B. Gómez-Anson,et al.  Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. , 2015, Journal of Alzheimer's disease : JAD.

[23]  D. Werring,et al.  White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid , 2015, Brain pathology.

[24]  Jaekwang Kim,et al.  Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms , 2014, Molecules and cells.

[25]  R. Sperling,et al.  Inflammatory cerebral amyloid angiopathy and amyloid‐modifying therapies: Variations on the Same ARIA? , 2013, Annals of neurology.

[26]  Antonio Colombo,et al.  Anti–amyloid β autoantibodies in cerebral amyloid angiopathy–related inflammation: Implications for amyloid‐modifying therapies , 2013, Annals of neurology.

[27]  Y. Hayashi,et al.  Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation , 2013, Journal of Neuroinflammation.

[28]  Nick C Fox,et al.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.

[29]  F. Barkhof,et al.  Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.

[30]  B. Borroni,et al.  Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease , 2012, Neurobiology of Aging.

[31]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[32]  S. Leurgans,et al.  Cerebral amyloid angiopathy pathology and cognitive domains in older persons , 2011, Annals of neurology.

[33]  I. Appollonio,et al.  Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1–42 antibodies in Alzheimer's disease patients , 2010, Neuroscience Letters.

[34]  B. Synek,et al.  Cerebral amyloid angiopathy related inflammation: three case reports and a review , 2010 .

[35]  N. Scolding,et al.  Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine , 2010, Journal of Neurology.

[36]  A. Maggi,et al.  Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. , 2010, Atherosclerosis.

[37]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[38]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.

[39]  K. Jellinger,et al.  Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.

[40]  B. Winblad,et al.  Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers? , 2016, Journal of Alzheimer's disease : JAD.

[41]  R. Levy,et al.  Recurrence of Cerebral Amyloid Angiopathy-Related Inflammation: A Report of Two Cases from the iCAβ International Network. , 2015, Journal of Alzheimer's disease : JAD.

[42]  J. Ferro,et al.  Cerebral Amyloid Angiopathy Associated with Inflammation: Report of 3 Cases and Systematic Review. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[43]  E. Parati,et al.  Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies. , 2015, Journal of Alzheimer's disease : JAD.

[44]  M. Uchino,et al.  Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature , 2011, Journal of Neuroinflammation.

[45]  D. Troost,et al.  OR PART OF THE FOLLOWING SOURCE ) : Type article Title Steroid responsive encephalopathy in cerebral amyloid angiopathy : a case report and review of evidence for immunosuppressive treatment , 2010 .